Wellington Keri, Curran Monique P
Adis International Limited, Auckland, New Zealand.
Drugs. 2004;64(22):2597-618. doi: 10.2165/00003495-200464220-00009.
Cefditoren pivoxil (Spectracef, Meiact) is a third-generation oral cephalosporin with a broad spectrum of activity against pathogens, including both Gram-positive and -negative bacteria, and is stable to hydrolysis by many common beta-lactamases. Cefditoren pivoxil is approved for use in the treatment of acute exacerbations of chronic bronchitis (AECB), mild-to-moderate community-acquired pneumonia (CAP), acute maxillary sinusitis, acute pharyngitis/tonsillitis and uncomplicated skin and skin structure infections (indications may differ between countries). In clinical trials in adults and adolescents, cefditoren pivoxil demonstrated good clinical and bacteriological efficacy in AECB, CAP, acute maxillary sinusitis, acute pharyngitis/tonsillitis and uncomplicated skin and skin structure infections and was generally well tolerated. Thus, cefditoren pivoxil is a good option for the treatment of adult and adolescent patients with specific respiratory tract or skin infections, particularly if there is concern about Streptococcus pneumoniae with decreased susceptibility to penicillin, or beta-lactamase-mediated resistance among the common community-acquired pathogens.
头孢妥仑匹酯（速可菲、美爱克）是一种第三代口服头孢菌素，对包括革兰氏阳性菌和革兰氏阴性菌在内的病原体具有广泛的抗菌活性，并且对多种常见的β-内酰胺酶的水解作用稳定。头孢妥仑匹酯已获批用于治疗慢性支气管炎急性加重（AECB）、轻至中度社区获得性肺炎（CAP）、急性上颌窦炎、急性咽炎/扁桃体炎以及单纯性皮肤及皮肤结构感染（不同国家的适应证可能有所不同）。在成人和青少年的临床试验中，头孢妥仑匹酯在AECB、CAP、急性上颌窦炎、急性咽炎/扁桃体炎以及单纯性皮肤及皮肤结构感染中显示出良好的临床和细菌学疗效，并且总体耐受性良好。因此，头孢妥仑匹酯是治疗患有特定呼吸道或皮肤感染的成人和青少年患者的一个良好选择，特别是当担心肺炎链球菌对青霉素的敏感性降低，或者常见社区获得性病原体中存在β-内酰胺酶介导的耐药性时。
